A Phase 3 interventional study of Zoster Vaccine, Live in Herpes Zoster and Varicella-zoster Vaccine, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 6th largest by enrollment, is one of 4 that started in 2011, is one of 9 in phase 3, and was the 11th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2011.
This study's enrollment of 600 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 16th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose. This information was compared to similar information obtained after Zoster Vaccine, Live administration to age-matched and younger participants who received their first dose of Zoster Vaccine, Live. The study was designed to determine: 1) whether a booster dose of Zoster Vaccine, Live in participants ≥70 years of age induces an antibody response that is noninferior to that of a first dose of Zoster Vaccine, Live in participants matched for age; 2) whether a booster dose of Zoster Vaccine, Live induces an acceptable rise in the level of varicella-zoster virus (VZV) antibodies.
All participants were followed for one year after completion of the 42-day post-vaccination period while Groups 1 and 2 were followed for a total of three years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Groups:
Group 1:
Group 2:
Group 3:
Group 4:
Exclusion Criteria:
All Groups:
Groups 2, 3, and 4:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
Biological: Zoster Vaccine, Live
Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
Biological: Zoster Vaccine, Live
Herpes zoster history-negative participants ≥60 and \<70 years of age who have never received Zoster Vaccine, Live
Biological: Zoster Vaccine, Live
Herpes zoster history-negative participants ≥50 and \<60 years of age who have never received Zoster Vaccine, Live
Biological: Zoster Vaccine, Live
Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
Also known as: V211, ZOSTAVAX™
Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)
VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)
Time frame: Day 1 (Baseline) and Week 6 postvaccination
Geometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers
VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.
Time frame: Day 1 (Baseline) and Week 6 postvaccination
Number of Participants Reporting One or More Adverse Experiences
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience. A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention. Vaccine-related AEs were those assessed by the investigator as definitely, probably, or possibly related to vaccine administration. This outcome measure applies only to AEs collected after vaccination in Part 1 of the current study.
Time frame: Up to 42 days postvaccination
| Milestone | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age |
|---|---|---|---|---|
| Started | 201 | 199 | 100 | 100 |
| Completed 42-day postvaccination period | 201 | 199 | 100 | 100 |
| Completed | 199 | 194 | 100 | 98 |
| Not completed | 2 | 5 | 0 | 2 |
| Withdrew: Death | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 | 0 |
| Milestone | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age |
|---|---|---|---|---|
| Started | 161 | 139 | 0 | 0 |
| Completed | 161 | 139 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)
| gpELISA Units/mL | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age |
|---|---|---|
| Day 1 (Baseline), n=201, 199 | 248.0 (219.7 to 280.0) | 254.2 (223.5 to 289.3) |
| Week 6 postvaccination, n=198, 195 | 389.1 (351.4 to 430.8) | 368.6 (330.5 to 411.6) |
VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.
| Fold Rise | Group 1: Booster Dose Participants ≥70 Years of Age |
|---|---|
| Geometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers | 1.5 (1.4 to 1.6) |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience. A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention. Vaccine-related AEs were those assessed by the investigator as definitely, probably, or possibly related to vaccine administration. This outcome measure applies only to AEs collected after vaccination in Part 1 of the current study.
| Participants | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age |
|---|---|---|---|---|
| Any Adverse Event | 104 | 95 | 72 | 72 |
| Injection-site Adverse Event | 68 | 61 | 56 | 57 |
| Non-Injection-site Adverse Event | 66 | 57 | 34 | 38 |
| Serious Adverse Event | 3 | 5 | 1 | 0 |
| Vaccine-related Serious Adverse Event | 0 | 0 | 0 | 0 |
Collected over Up to 42 days postvaccination: all AEs; Day 43 to Week 52: SAEs only; Week 156: SAEs only within 24 hours of the Week-156 blood draw (Groups 1 and 2 only). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Booster Dose Participants ≥70 Years of Age | — | 29/201 (14.4%) | 76/201 (37.8%) |
| Group 2: First Dose Participants ≥70 Years of Age | — | 29/199 (14.6%) | 58/199 (29.1%) |
| Group 3: First Dose Participants ≥60 and <70 Years of Age | — | 6/100 (6%) | 61/100 (61%) |
| Group 4: First Dose Participants ≥50 and <60 Years of Age | — | 2/100 (2%) | 62/100 (62%) |
| Event | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age |
|---|---|---|---|---|
| SyncopeNervous system disorders | 1/201 | 3/199 | 0/100 | 0/100 |
| IleusGastrointestinal disorders | 0/201 | 2/199 | 0/100 | 0/100 |
| Atrial FibrillationCardiac disorders | 1/201 | 2/199 | 1/100 | 0/100 |
| Acute kidney injuryRenal and urinary disorders | 0/201 | 2/199 | 1/100 | 0/100 |
| Wound haemorrhageInjury, poisoning and procedural complications | 0/201 | 0/199 | 1/100 | 0/100 |
| Coronary artery diseaseCardiac disorders | 0/201 | 0/199 | 1/100 | 0/100 |
| Abdominal herniaGastrointestinal disorders | 0/201 | 0/199 | 1/100 | 0/100 |
| Large intestinal ulcer haemorrhageGastrointestinal disorders | 0/201 | 0/199 | 1/100 | 0/100 |
| RhinitisInfections and infestations | 0/201 | 0/199 | 1/100 | 0/100 |
| Procedural hypertensionInjury, poisoning and procedural complications | 0/201 | 0/199 | 1/100 | 0/100 |
| Event | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age |
|---|---|---|---|---|
| Injection-site painGeneral disorders | 47/201 | 28/199 | 42/100 | 48/100 |
| Injection-site erythemaGeneral disorders | 44/201 | 47/199 | 41/100 | 40/100 |
| Injection-site swellingGeneral disorders | 31/201 | 24/199 | 29/100 | 33/100 |
| Injection-site pruritusGeneral disorders | 10/201 | 9/199 | 9/100 | 11/100 |
| HeadacheNervous system disorders | 8/201 | 4/199 | 3/100 | 9/100 |
| NasopharyngitisInfections and infestations | 11/201 | 2/199 | 5/100 | 7/100 |
| Age, Continuous(years) | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age | Total |
|---|---|---|---|---|---|
| Mean | 77.1 ± 4.5 | 76.3 ± 5.1 | 64.1 ± 3.1 | 55.5 ± 2.8 | 71.1 ± 9.4 |
| Sex: Female, Male(Participants) | Group 1: Booster Dose Participants ≥70 Years of Age | Group 2: First Dose Participants ≥70 Years of Age | Group 3: First Dose Participants ≥60 and <70 Years of Age | Group 4: First Dose Participants ≥50 and <60 Years of Age | Total |
|---|---|---|---|---|---|
| Female | 107 | 94 | 65 | 77 | 343 |
| Male | 94 | 105 | 35 | 23 | 257 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Apr 2011, a primary completion of Jul 2012 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine